Bartosz Bieszczad

Mr. Bartosz Bieszczad

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
BBBartosz Bieszczad
Bartosz Bieszczad
DGDamian Garbicz
Damian Garbicz
MŚMarta Świtalska
Marta Świtalska
MDMarta Dudek
Marta Dudek
DWDawid Warszycki
Dawid Warszycki
AMAdam Mieczkowski
Adam Mieczkowski
Histone deacetylase (HDAC) inhibitors are a class of drugs used in the cancer treatment. Here, we developed a library of 19 analogues of Vorinostat, an HDAC inhibitor used in lymphomas treatment. In Vorinostat, we replaced the hydrophobic phenyl group with various tricyclic ‘caps’ possessing a central, eight-membered, heterocyclic ring, and investigated the HDAC activity and cytotoxic effect on the cancer and normal cell lines. We found that 3 out of the 19 compounds, based on dibenzo[b,f]azocin-6(5H)-one, 11,12-dihydrodibenzo[b,f]azocin-6(5H)-one, and benzo[b]naphtho[2,3-f][1,5]diazocine-6,14(5H,13H)-dione scaffolds, showed better HDACs inhibition than the referenced Vorinostat. In leukemic cell line MV4-11 and in the lymphoma cell line Daudi, three compounds showed lower IC50 values than Vorinostat. These compounds had higher activity and selectivity against MV4-11 and Daudi cell lines than reference Vorinostat. We also observed a strong correlation between HDACs inhibition and the cytotoxic effect. Cell lines derived from solid tumours: A549 (lung carcinoma) and MCF-7 (breast adenocarcinoma) as well as reference BALB/3T3 (normal murine fibroblasts) were less susceptible to compounds tested. Developed derivatives show improved properties than Vorinostat, thus they could be considered as possible agents for leukemia and lymphoma treatment.

18 February 2020 in Molecules
Verified
Journal Article
Open access
PDF file
BBBartosz Bieszczad
Bartosz Bieszczad
DGDamian Garbicz
Damian Garbicz
DTDamian Trzybiński
Damian Trzybiński
DMDamian Mielecki
Damian Mielecki
KWKrzysztof Woźniak
Krzysztof Woźniak
AMAdam Mieczkowski
Adam Mieczkowski
A novel approach for the synthesis of unsymmetrically substituted dibenzo[b,f][1,5]diazocine-6,12(5H,11H)diones has been developed. This facile three-step method uses variously substituted 1H-benzo[d][1,3]oxazine-2,4-diones (isatoic anhydrides) and 2-aminobenzoic acids as a starting materials. The obtained products were further transformed into N-alkyl-, N-acetyl- and dithio analogues. Developed procedures allowed the synthesis of unsymmetrical dibenzo[b,f][1,5]diazocine-6,12(5H,11H)diones and three novel heterocyclic scaffolds: benzo[b]naphtho[2,3-f][1,5]diazocine-6,14(5H,13H)dione, pyrido[3,2-c][1,5]benzodiazocine-5,11(6H,12H)-dione and pyrazino[3,2-c][1,5]benzodiazocine-6,12(5H,11H)dione. For 11 of the compounds crystal structures were obtained. The preliminary cytotoxic effect against two cancer (HeLa, U87) and two normal lines (HEK293, EUFA30) as well as antibacterial activity were determined. The obtained dibenzo[b,f][1,5]diazocine(5H,11H)6,12-dione framework could serve as a privileged structure for the drug design and development.

1 November 2020 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
BBBartosz Bieszczad
Bartosz Bieszczad
ASAgata Siwek
Agata Siwek
MWMarcin Wilczek
Marcin Wilczek
DTDamian Trzybiński
Damian Trzybiński
KWKrzysztof Woźniak
Krzysztof Woźniak
AMAdam Mieczkowski
Adam Mieczkowski

27 October 2017 in Molbank
Verified
Journal Article
Open access
PDF file
AMAdam Mieczkowski
Adam Mieczkowski
DTDamian Trzybiński
Damian Trzybiński
MWMarcin Wilczek
Marcin Wilczek
MPMateusz Psurski
Mateusz Psurski
MBMaciej Bagiński
Maciej Bagiński
KWKrzysztof Woźniak
Krzysztof Woźniak
(S)-2-(4-Chlorobenzoyl)-1,2,3,4-tetrahydrobenzo[e]pyrazino[1,2-a][1,4]diazepine-6,12(11H,12aH)-dione was obtained in a three-step, one-pot synthesis, starting from optically pure (S)-2-piperazine carboxylic acid dihydrochloride. Selective acylation of the β-nitrogen atom followed by condensation with isatoic anhydride and cyclization with HATU/DIPEA to a seven-member benzodiazepine ring, led to the tricyclic benzodiazepine derivative. Crystallographic studies and initial biological screening were performed for the title compound.

5 August 2020 in CrystEngComm
Verified
Journal Article
Closed access
PDF file
BBBartosz Bieszczad
Bartosz Bieszczad
SPSylwia Pawlędzio
Sylwia Pawlędzio
KPKatarzyna Polak
Katarzyna Polak
JAJerzy Antonowicz
Jerzy Antonowicz
AMAdam Mieczkowski
Adam Mieczkowski
DTDamian Trzybiński
Damian Trzybiński
The synthesis, crystallisation and detailed description of the crystal structure of the THF solvates of four halogen (F, Cl, Br and I) derivatives of dianthranilide (5H,11H-dibenzo[b,f][1,5]diazocine-6,12-dione) have been reported. The influence of the halogen size on the conformation of the halogen derivative, the overall supramolecular architecture including the existing scheme of intermolecular interactions and the selected energy issues have been discussed in detail. The solvates which are described in this paper exhibit an interesting arrangement of molecules in their crystals resembling a “honeycomb”. The variety of interactions between the respective molecules, including hydrogen bonds, halogen-mediated noncovalent interactions and π–π contacts, makes them an attractive target for crystallographic studies. The results of our analysis may lead to a better understanding of the role of a halogen functional group in the rational design of specific multicomponent crystalline networks based on compounds consisting of two substituted phenyl rings separated by a fused heterocyclic moiety.

20 June 2020 in Molecules
Verified
Journal Article
Open access
PDF file
BBBartosz Bieszczad
Bartosz Bieszczad
DGDamian Garbicz
Damian Garbicz
DTDamian Trzybiński
Damian Trzybiński
MDMarta K. Dudek
Marta K. Dudek
KWKrzysztof Woźniak
Krzysztof Woźniak
AMAdam Mieczkowski
Adam Mieczkowski
Unsymmetrically N-substituted and N,N’-disubstituted 5,12-dihydrodibenzo [b,f][1,4]diazocine-6,11-diones were synthesized in the new protocol. The desired modifications of the dibenzodiazocine scaffold were introduced at the stages of proper selection of building blocks as well as post-cyclization modifications with alkylation or acylation agents, expanding the structural diversity and possible applications of synthesized molecules. The extension of developed method resulted in the synthesis of novel: tricyclic 5,10-dihydrobenzo[b]thieno[3,4-f][1,4]diazocine-4,11-dione scaffold and fused pentacyclic framework possessing two benzodiazocine rings within its structure. Additionally, the unprecedented rearrangement of 5,12-dihydrodibenzo[b,f][1,4]diazocine-6,11-diones to 2-(2-aminophenyl)isoindoline-1,3-diones was observed under the basic conditions in the presence of sodium hydride for secondary dilactams. The structures of nine synthesized products have been established by single-crystal X-ray diffraction analysis. Detailed crystallographic analysis of the investigated tri- and pentacyclic systems has shed more light on their structural features. One cell line derived from non-cancerous cells (EUFA30—human fibroblasts) and three tumor cells (U87—human primary glioblastoma, HeLa—cervix adenocarcinoma, BICR18—laryngeal squamous cell carcinoma) were used to determine the cytotoxic effect of the newly synthesized compounds. Although these compounds showed a relatively weak cytotoxic effect, the framework obtained for 5,12-dihydrodibenzo[b,f][1,4]diazocine-6,11-dione could serve as a convenient privilege structure for the design and development of novel bioactive molecules suitable for drug design, development and optimization programs.